Conclusion
While there is a lack of strong evidence to support the use of CBE in ASD, this case report provides the first insight about lower than previously reported doses of phytocannabinoids in the form of CBE, which may benefit ASD-related behavioral and core social symptoms, as well as anxiety, sleep disturbances, and weight. We encourage scientists and clinicians to pioneer placebo-controlled studies to validate the clinical efficacy of very low doses of CBE in a larger cohort.
Abbreviations
AEA: Anandamide; ASD: Autism spectrum disorder; ECS: Endocannabinoid system; FDA: Food and Drug Administration; CAM: Complementary and alternative medicine; CBD: Cannabidiol; CT: Computed tomography; CYMH: Child and Youth Mental Health; FAAH: Fatty amide acid hydrolase; THC: Delta-9-tetrahydrocannabinol; CBE: Cannabidiol-based extract; IHCA N: Interior Health Children's Assessment Network; MRI: Magnetic resonance imaging; SL: Sublingual; ADI-R: Autism Diagnostic Interview – Revised; ADOS-2: Autism Diagnostic Observation Schedule 2; ACH: Alberta Children's Hospital; VPA: Valproic acid; BMI: Body mass index; BC: British Columbia; VAS: Visual analog scale; CSHQ: Children's Sleep Habits Questionnaire; AQ: Autism Spectrum Quotient
Acknowledgements
We want to thank Caleo Health and all the administrative staff. Special thanks to Michelle Andoy for supporting us
Funding
WAM provided all the funding.
Availability of data and materials
The dataset generated and analyzed during this case report are available in Netcare (Alberta's public Electronic Health Record used to store patient information).
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient's legal guardian for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
J Med Case Reports. 2020;14(162) © 2020 BioMed Central, Ltd.
